Successful Treatment of Refractory Dermatomyositis with Deucravacitinib (Sotyktu): A Case Report
This case highlights deucravacitinib as a potential treatment option for refractory CADM. By selectively inhibiting TYK2, it targets key inflammatory pathways involved in DM pathogenesis while minimizing off-target effects. Further studies are needed to evaluate its long-term safety and efficacy in this patient population.
Authors
- Maksym Breslavets (ORCID: https://orcid.org/0009-0000-4999-5940)
- Tatiana Lapa (ORCID: https://orcid.org/0000-0001-9937-4755)
Institutions
- University of Toronto (CA)
Publication Details
- Journal
- Case Reports in Dermatology
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1159/000548207
- Citations
- 1
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 1.35